Medifast has spent the past few quarters asking investors to look past a shrinking top line and focus on the quality of its remaining coach network. Its third-quarter report, due before the open on October 26, is where that argument has to start showing up in the numbers. Under new CEO Nick Johnson, management has promised a return to profitability in the fourth quarter. That leaves this report as the last checkpoint before the promise comes due.
The Street is braced for a deeper loss. Consensus calls for a loss of $0.40 per share on revenue of $68.0 million. Revenue would fall about 24% from the $89.4 million posted a year ago and about 11% from the second quarter's $76.4 million. The projected loss is nearly double the $0.21 deficit of the year-ago quarter and wider than last quarter's $0.28. Management guided to a loss of $0.15 to $0.65 on revenue of $60 million to $80 million, so the EPS estimate sits squarely at the midpoint. Revenue expectations lean slightly toward the lower half. Notably, analysts have moved up from a $0.60 loss estimate since the guidance was issued, which suggests some confidence that cost discipline will cushion the decline. It also means the easy beat is no longer quite so easy.
The bull case rests on coach productivity. Revenue per active earning coach climbed to $6,529 last quarter, up 41% from a year earlier and the highest level since 2022. That marked the third straight quarter of acceleration. The problem is that the coach base keeps shrinking, falling to roughly 11,700, nearly half its year-ago size. So far productivity gains have only offset attrition, which is why sales sat near $75 million to $76 million for three quarters. A sequential drop toward $68 million would mean that offset is weakening. If revenue lands near or above the high end of guidance, or if coach declines slow meaningfully, the stabilization story gains real credibility. Another quarter of steep coach losses paired with flattening productivity would challenge it.
Several new initiatives need early evidence. These include the Trilivi brand replacing Optavia, new Reset fuelings on the Medivantage platform and the Metabolic Health Institute launched in July. An executive-director-focused compensation plan also took effect August 1. Management pointed to a sold-out convention and record referral activity as signs of field energy. This quarter offers the first look at whether that engagement converts into new clients and coach recruitment rather than simply sustaining a loyal core.
Margins are the other swing factor. Gross margin slipped to 69.9% last quarter from 72.6% a year earlier, and the operating loss widened as fixed costs were spread over less revenue. The Catalyst cost program is meant to fix that, but management has not quantified the savings. Any concrete figure, along with a gross margin that holds near 70% on lower sales, would make the fourth-quarter profit target look more achievable. The full-year guide of a $0.25 to $1.75 loss, improved from the prior range, also implies a meaningful second-half swing. A full deferred-tax valuation allowance continues to distort the tax line and could muddy the bottom-line read.
The market has stayed noncommittal. Shares are down 1.3% since the last report, trailing the S&P 500 by about 1.6 percentage points. At $11.88, the stock sits in the lower half of its post-earnings range of $11.26 to $13.45, just above its 200-day moving average, which coincides with that range's low. Sentiment has edged up to 28.1% bullish from 25.7%, a modest improvement that hardly signals euphoria.
The central question is whether rising productivity can finally outrun a shrinking coach base. Fresh evidence of Catalyst savings and early traction from the Trilivi relaunch would keep the turnaround narrative intact. Without that, the fourth-quarter profitability pledge starts to look like a stretch rather than a plan.